Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells

Free Radical Biology and Medicine

Volumn 74, Issue , 2014, Pages 129-144

  Ribeiro, Márcio ^a   Rosenstock, Tatiana R ^a   Oliveira, Ana M ^a   Oliveira, Catarina R ^a,b   Rego, A Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Akt; Huntington disease; Insulin IGF 1 signaling; Mitochondria; Nrf2; Oxidative stress; Reactive oxygen species; Striatal cells

Indexed keywords

CYTOCHROME C OXIDASE; DYNAMIN I; GLUTATHIONE; HUNTINGTIN; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; DNA BINDING PROTEIN; DNM1L PROTEIN, MOUSE; DYNAMIN; HDH PROTEIN, MOUSE; HIGH MOBILITY GROUP PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; TFAM PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; BRAIN CELL; CELL FUNCTION; CELL MUTANT; CONTROLLED STUDY; ENZYME ACTIVITY; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRIATAL CELL; TRANSCRIPTION INITIATION; ANIMAL; CELL CULTURE; CORPUS STRIATUM; DRUG EFFECTS; GENETICS; HUMAN; HUNTINGTON DISEASE; INBRED MOUSE STRAIN; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CORPUS STRIATUM; DNA-BINDING PROTEINS; DYNAMINS; HIGH MOBILITY GROUP PROTEINS; HUMANS; HUNTINGTON DISEASE; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; REACTIVE OXYGEN SPECIES;

EID: 84904892173     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.06.023     Document Type: Article

References (98)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
2. J.M. Gil, and A.C. Rego Mechanisms of neurodegeneration in Huntington's disease Eur. J. Neurosci. 27 2008 2803 2820 (Pubitemid 351832229)
3. T.R. Rosenstock, A.I. Duarte, and A.C. Rego Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench Curr. Drug Targets 11 2010 1218 1236
4. S.M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, A.M. Ulug, M.F. Beal, W. Matson, M. Bogdanov, E. Ebbel, A. Zaleta, Y. Kaneko, B. Jenkins, N. Hevelone, H. Zhang, H. Yu, D. Schoenfeld, R. Ferrante, and H.D. Rosas Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG Neurology 66 2006 250 252 (Pubitemid 43970166)
5. C.M. Chen, Y.R. Wu, M.L. Cheng, J.L. Liu, Y.M. Lee, P.W. Lee, B.W. Soong, and D.T. Chiu Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients Biochem. Biophys. Res. Commun. 359 2007 335 340 (Pubitemid 46880509)
6. I. Tunez, F. Sanchez-Lopez, E. Aguera, R. Fernandez-Bolanos, F.M. Sanchez, and I. Tasset-Cuevas Important role of oxidative stress biomarkers in Huntington's disease J. Med. Chem. 54 2011 5602 5606
7. S.E. Browne, A.C. Bowling, U. MacGarvey, M.J. Baik, S.C. Berger, M.M. Muqit, E.D. Bird, and M.F. Beal Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia Ann. Neurol. 41 1997 646 653 (Pubitemid 27212659)
8. M.C. Polidori, P. Mecocci, S.E. Browne, U. Senin, and M.F. Beal Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex Neurosci. Lett. 272 1999 53 56
9. U. Shirendeb, A.P. Reddy, M. Manczak, M.J. Calkins, P. Mao, D.A. Tagle, and P.H. Reddy Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage Hum. Mol. Genet 20 2011 1438 1455
10. M.B. Bogdanov, O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, and M.F. Beal Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease J. Neurochem. 79 2001 1246 1249 (Pubitemid 34019802)
11. N. Stoy, G.M. Mackay, C.M. Forrest, J. Christofides, M. Egerton, T.W. Stone, and L.G. Darlington Tryptophan metabolism and oxidative stress in patients with Huntington's disease J. Neurochem. 93 2005 611 623 (Pubitemid 40617621)
12. S.E. Browne, R.J. Ferrante, and M.F. Beal Oxidative stress in Huntington's disease Brain Pathol. 9 1999 147 163 (Pubitemid 29056525)
13. J. Lee, B. Kosaras, S.J. Del Signore, K. Cormier, A. McKee, R.R. Ratan, N.W. Kowall, and H. Ryu Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice Acta Neuropathol. 121 2011 487 498
14. S.J. Tabrizi, J. Workman, P.E. Hart, L. Mangiarini, A. Mahal, G. Bates, J.M. Cooper, and A.H. Schapira Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Ann. Neurol. 47 2000 80 86 (Pubitemid 30033653)
15. S. Hands, M.U. Sajjad, M.J. Newton, and A. Wyttenbach in vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production J. Biol. Chem. 286 2011 44512 44520
16. M.A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Ros, and E. Cabiscol Proteomic and oxidative stress analysis in human brain samples of Huntington disease Free Radic. Biol. Med. 45 2008 667 678
17. M. Ribeiro, T.R. Rosenstock, T. Cunha-Oliveira, I.L. Ferreira, C.R. Oliveira, and A.C. Rego Glutathione redox cycle dysregulation in Huntingtons disease knock-in striatal cells Free Radic. Biol. Med. 53 2012 1857 1867
18. M.E. Ehrlich Huntingtons disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease Neurotherapeutics 9 2012 270 284
19. A.C. Silva, S. Almeida, M. Laco, A.I. Duarte, J. Domingues, C.R. Oliveira, C. Januario, and A.C. Rego Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntingtons disease carriers Mitochondrion 13 2013 801 809
20. E. Napoli, S. Wong, C. Hung, C. Ross-Inta, P. Bomdica, and C. Giulivi Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntingtons disease Hum. Mol. Genet 22 2013 989 1004
21. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntingtons disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736 (Pubitemid 34827590)
22. J.M. Oliveira, S. Chen, S. Almeida, R. Riley, J. Goncalves, C.R. Oliveira, M.R. Hayden, D.G. Nicholls, L.M. Ellerby, and A.C. Rego Mitochondrial-dependent Ca2+ handling in Huntingtons disease striatal cells: effect of histone deacetylase inhibitors J. Neurosci. 26 2006 11174 11186 (Pubitemid 44772205)
23. A. Siddiqui, S. Rivera-Sanchez, R. Castro Mdel, K. Acevedo-Torres, A. Rane, C.A. Torres-Ramos, D.G. Nicholls, J.K. Andersen, S. Ayala-Torres, and DNA Mitochondrial damage is associated with reduced mitochondrial bioenergetics in Huntingtons disease Free Radic. Biol. Med. 53 2012 1478 1488
24. Z. Xun, S. Rivera-Sanchez, S. Ayala-Pena, J. Lim, H. Budworth, E.M. Skoda, P.D. Robbins, L.J. Niedernhofer, P. Wipf, and C.T. McMurray Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntingtons disease Cell Rep 2 2012 1137 1142
25. Y.S. Choo, G.V. Johnson, M. MacDonald, P.J. Detloff, and M. Lesort Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release Hum. Mol. Genet 13 2004 1407 1420 (Pubitemid 39023049)
26. M.A. Pouladi, Y. Xie, N.H. Skotte, D.E. Ehrnhoefer, R.K. Graham, J.E. Kim, N. Bissada, X.W. Yang, P. Paganetti, R.M. Friedlander, B.R. Leavitt, and M.R. Hayden Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression Hum. Mol. Genet 19 2010 1528 1538
27. S. Humbert, E.A. Bryson, F.P. Cordelieres, N.C. Connors, S.R. Datta, S. Finkbeiner, M.E. Greenberg, and F. Saudou The IGF-1/Akt pathway is neuroprotective in Huntingtons disease and involves Huntingtin phosphorylation by Akt Dev. Cell 2 2002 831 837 (Pubitemid 34650078)
28. S. Gines, E. Ivanova, I.S. Seong, C.A. Saura, and M.E. MacDonald Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntingtons disease knock-in striatal cells J. Biol. Chem. 278 2003 50514 50522 (Pubitemid 37548897)
29. A.I. Duarte, G.H. Petit, S. Ranganathan, J.Y. Li, C.R. Oliveira, P. Brundin, M. Bjorkqvist, and A.C. Rego IGF-1 protects against diabetic features in an in vivo model of Huntingtons disease Exp. Neurol. 231 2011 314 319
30. Lopes, C.; Ribeiro, M.; Duarte, A. I.; Humbert, S.; Saudou, F.de Almeida, L.P.; Hayden, M.; Rego, A.C.IGF-1 Intranasal Administration Rescues Huntingtons Disease Phenotypes in YAC128 Mice. Mol. Neurobiol. In press; 2013.
31. A.I. Duarte, P. Santos, C.R. Oliveira, M.S. Santos, and A.C. Rego Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression Biochim. Biophys. Acta 1783 2008 994 1002
32. W. Langston, M.L. Circu, and T.Y. Aw Insulin stimulation of gamma-glutamylcysteine ligase catalytic subunit expression increases endothelial GSH during oxidative stress: influence of low glucose Free Radic. Biol. Med. 45 2008 1591 1599
33. Y.N. Jin, Y.V. Yu, S. Gundemir, C. Jo, M. Cui, K. Tieu, and G.V. Johnson Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin PLoS One 8 2013 e57932
34. X. Gan, S. Huang, L. Wu, Y. Wang, G. Hu, G. Li, H. Zhang, H. Yu, R.H. Swerdlow, J.X. Chen, and S.S. Yan Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimers disease cybrid cell Biochim. Biophys. Acta 1842 2014 220 231
35. C. Li, Y. Li, L. He, A.R. Agarwal, N. Zeng, E. Cadenas, and B.L. Stiles PI3K/AKT signaling regulates bioenergetics in immortalized hepatocytes Free Radic. Biol. Med. 60 2013 29 40
36. P. Mookherjee, R. Quintanilla, M.S. Roh, A.A. Zmijewska, R.S. Jope, and G.V. Johnson Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death J. Cell. Biochem. 102 2007 196 210 (Pubitemid 47378922)
37. Wang, K. Z.; Zhu, J.; Dagda, R. K.; Uechi, G.; Cherra, S. J. 3rd, Gusdon, A.M.; Balasubramani, M.; Chu, C. T. ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: Implications for Parkinsons diseaseMitochondrion; 2014.
38. F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V.C. Wheeler, A.H. Sharp, F. Persichetti, E. Cattaneo, and M.E. MacDonald Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells Hum. Mol. Genet 9 2000 2799 2809
39. C.P. LeBel, H. Ischiropoulos, and S.C. Bondy Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress Chem. Res. Toxicol. 5 1992 227 231
40. V.P. Bindokas, J. Jordan, C.C. Lee, and R.J. Miller Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine J. Neurosci. 16 1996 1324 1336 (Pubitemid 26145913)
41. E.C. Filippi-Chiela, M.M. Oliveira, B. Jurkovski, S.M. Callegari-Jacques, V.D. da Silva, and G. Lenz Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities PLoS One 7 2012 e42522
42. D.G. Nicholls Fluorescence measurement of mitochondrial membrane potential changes in cultured cells Methods Mol. Biol. 810 2012 119 133
43. I.L. Ferreira, M.V. Nascimento, M. Ribeiro, S. Almeida, S.M. Cardoso, M. Grazina, J. Pratas, M.J. Santos, C. Januario, C.R. Oliveira, and A.C. Rego Mitochondrial-dependent apoptosis in Huntingtons disease human cybrids Exp. Neurol. 222 2010 243 255
44. M.M. Rechler, J. Zapf, S.P. Nissley, E.R. Froesch, A.C. Moses, J.M. Podskalny, E.E. Schilling, and R.E. Humbel Interactions of insulin-like growth factors I and II and multiplication-stimulating activity with receptors and serum carrier proteins Endocrinology 107 1980 1451 1459 (Pubitemid 10029739)
45. K.M. Robinson, M.S. Janes, and J.S. Beckman The selective detection of mitochondrial superoxide by live cell imaging Nat. Protoc. 3 2008 941 947 (Pubitemid 351818682)
46. B. Kalyanaraman, V. Darley-Usmar, K.J. Davies, P.A. Dennery, H.J. Forman, M.B. Grisham, G.E. Mann, K. Moore, L.J. Roberts 2nd, and H. Ischiropoulos Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations Free Radic. Biol. Med. 52 2012 1 6
47. D. Lim, L. Fedrizzi, M. Tartari, C. Zuccato, E. Cattaneo, M. Brini, and E. Carafoli Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease J. Biol. Chem. 283 2008 5780 5789
48. T.R. Rosenstock, O.M. de Brito, V. Lombardi, S. Louros, M. Ribeiro, S. Almeida, I.L. Ferreira, C.R. Oliveira, and A.C. Rego FK506 ameliorates cell death features in Huntingtons disease striatal cell models Neurochem. Int. 59 2011 600 609
49. M. Ribeiro, A.C. Silva, J. Rodrigues, L. Naia, and A.C. Rego Oxidizing effects of exogenous stressors in Huntingtons disease knock-in striatal cells - protective effect of cystamine and creatine Toxicol. Sci. 136 2013 487 499
50. Y. Chen, J. Zhang, Y. Lin, Q. Lei, K.L. Guan, S. Zhao, and Y. Xiong Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS EMBO Rep. 12 2011 534 541
51. K. Nakaso, H. Yano, Y. Fukuhara, T. Takeshima, K. Wada-Isoe, and K. Nakashima PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells FEBS Lett. 546 2003 181 184 (Pubitemid 36782407)
52. P. Moi, K. Chan, I. Asunis, A. Cao, and Y.W. Kan Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region Proc. Natl. Acad. Sci. USA 91 1994 9926 9930 (Pubitemid 24311921)
53. A. Lau, W. Tian, S.A. Whitman, and D.D. Zhang The predicted molecular weight of Nrf2: it is what it is not Antioxid. Redox Signal. 18 2013 91 93
54. H.C. Huang, T. Nguyen, and C.B. Pickett Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription J. Biol. Chem. 277 2002 42769 42774 (Pubitemid 35285650)
55. S. Fourquet, R. Guerois, D. Biard, and M.B. Toledano Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation J. Biol. Chem. 285 2010 8463 8471
56. E.E. Vincent, D.J. Elder, E.C. Thomas, L. Phillips, C. Morgan, J. Pawade, M. Sohail, M.T. May, M.R. Hetzel, and J.M. Tavare Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer Br. J. Cancer 104 2011 1755 1761
57. A. Hahn-Windgassen, V. Nogueira, C.C. Chen, J.E. Skeen, N. Sonenberg, and N. Hay Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity J. Biol. Chem. 280 2005 32081 32089 (Pubitemid 41361813)
58. B. Mayr, and M. Montminy Transcriptional regulation by the phosphorylation-dependent factor CREB Nat. Rev. Mol. Cell. Biol. 2 2001 599 609 (Pubitemid 33674011)
59. L. Cui, H. Jeong, F. Borovecki, C.N. Parkhurst, N. Tanese, and D. Krainc Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 127 2006 59 69 (Pubitemid 44466642)
60. S.Y. Cong, B.A. Pepers, B.O. Evert, D.C. Rubinsztein, R.A. Roos, G.J. van Ommen, and J.C. Dorsman Mutant huntingtin represses CBP, but not p300, by binding and protein degradation Mol. Cell. Neurosci. 30 2005 560 571
61. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, H. Gohler, E.E. Wanker, G.P. Bates, D.E. Housman, and L.M. Thompson The Huntingtons disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. USA 97 2000 6763 6768 (Pubitemid 30412788)
62. U.P. Shirendeb, M.J. Calkins, M. Manczak, V. Anekonda, B. Dufour, J.L. McBride, P. Mao, and P.H. Reddy Mutant huntingtins interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntingtons disease Hum. Mol. Genet 21 2012 406 420
63. W. Song, J. Chen, A. Petrilli, G. Liot, E. Klinglmayr, Y. Zhou, P. Poquiz, J. Tjong, M.A. Pouladi, M.R. Hayden, E. Masliah, M. Ellisman, I. Rouiller, R. Schwarzenbacher, B. Bossy, G. Perkins, and E. Bossy-Wetzel Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity Nat. Med 17 2011 377 382
64. B. Cho, S.Y. Choi, H.M. Cho, H.J. Kim, and W. Sun Physiological and pathological significance of dynamin-related protein 1 (Drp1)-dependent mitochondrial fission in the nervous system Exp. Neurobiol 22 2013 149 157
65. C.J. Vlahos, W.F. Matter, K.Y. Hui, and R.F. Brown A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002) J. Biol. Chem. 269 1994 5241 5248
66. S. Namura, K. Iihara, S. Takami, I. Nagata, H. Kikuchi, K. Matsushita, M.A. Moskowitz, J.V. Bonventre, and A. Alessandrini Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia Proc. Natl. Acad. Sci. USA 98 2001 11569 11574 (Pubitemid 32928769)
67. D.J. Roberts, V.P. Tan-Sah, J.M. Smith, and S. Miyamoto Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes J. Biol. Chem. 288 2013 23798 23806
68. L. Kapustian, I. Kroupskaya, O. Rozhko, V. Bobyk, D. Ryabenko, and L. Sidorik Akt1 expression and activity at different stages in experimental heart failure Pathophysiology 2013
69. C.A. Piantadosi, and H.B. Suliman Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1 J. Biol. Chem. 281 2006 324 333 (Pubitemid 43671192)
70. A. Santamaria, F. Perez-Severiano, E. Rodriguez-Martinez, P.D. Maldonado, J. Pedraza-Chaverri, C. Rios, and J. Segovia Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntingtons disease Neurochem. Res. 26 2001 419 424 (Pubitemid 32691133)
71. W.M. van Roon-Mom, B.A. Pepers, P.A. t Hoen, C.A. Verwijmeren, J.T. den Dunnen, J.C. Dorsman, and G.B. van Ommen Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntingtons disease BMC Mol. Biol. 9 2008 84
72. Z. Sun, Y.E. Chin, and D.D. Zhang Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response Mol. Cell. Biol. 29 2009 2658 2672
73. J. Gil, S. Almeida, C.R. Oliveira, and A.C. Rego Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis Free Radic. Biol. Med. 35 2003 1500 1514 (Pubitemid 37452475)
74. A.I. Duarte, M.S. Santos, C.R. Oliveira, and A.C. Rego Insulin neuroprotection against oxidative stress in cortical neurons - involvement of uric acid and glutathione antioxidant defenses Free Radic. Biol. Med. 39 2005 876 889
75. E. Colin, E. Regulier, V. Perrin, A. Durr, A. Brice, P. Aebischer, N. Deglon, S. Humbert, and F. Saudou Akt is altered in an animal model of Huntingtons disease and in patients Eur. J. Neurosci. 21 2005 1478 1488 (Pubitemid 40646594)
76. V. Maglione, P. Marchi, A. Di Pardo, S. Lingrell, M. Horkey, E. Tidmarsh, and S. Sipione Impaired ganglioside metabolism in Huntingtons disease and neuroprotective role of GM1 J. Neurosci. 30 2010 4072 4080
77. E. Nagata, A. Saiardi, H. Tsukamoto, Y. Okada, Y. Itoh, T. Satoh, J. Itoh, R.L. Margolis, S. Takizawa, A. Sawa, and S. Takagi Inositol hexakisphosphate kinases induce cell death in Huntington disease J. Biol. Chem. 286 2011 26680 26686
78. D. Zala, E. Colin, H. Rangone, G. Liot, S. Humbert, and F. Saudou Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons Hum. Mol. Genet 17 2008 3837 3846 (Pubitemid 352762847)
79. S.C. Warby, E.Y. Chan, M. Metzler, L. Gan, R.R. Singaraja, S.F. Crocker, H.A. Robertson, and M.R. Hayden Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo Hum. Mol. Genet 14 2005 1569 1577 (Pubitemid 40823464)
80. M. Sadagurski, Z. Cheng, A. Rozzo, I. Palazzolo, G.R. Kelley, X. Dong, D. Krainc, and M.F. White IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease J. Clin. Invest. 121 2011 4070 4081
81. A. Yamamoto, M.L. Cremona, and J.E. Rothman Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway J. Cell. Biol. 172 2006 719 731
82. F. Mochel, P. Charles, F. Seguin, J. Barritault, C. Coussieu, L. Perin, Y. Le Bouc, C. Gervais, G. Carcelain, A. Vassault, J. Feingold, D. Rabier, and A. Durr Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression PLoS One 2 2007 e647
83. N. Saleh, S. Moutereau, J.P. Azulay, C. Verny, C. Simonin, C. Tranchant, N. El Hawajri, A.C. Bachoud-Levi, and P. Maison Huntington French Speaking, G. High insulinlike growth factor I is associated with cognitive decline in Huntington disease Neurology 75 2010 57 63
84. Naia, L.; Ferreira, I. L.; Cunha-Oliveira, T.; Duarte, A. I.; Ribeiro, M.; Rosenstock, T. R.; Laco, M. N.; Ribeiro, M. J.; Oliveira, C. R.; Saudou, F.; Humbert, S.; Rego, A. C. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntingtons disease human lymphoblasts. Mol Neurobiol; 2014.
85. B.L. Apostol, K. Illes, J. Pallos, L. Bodai, J. Wu, A. Strand, E.S. Schweitzer, J.M. Olson, A. Kazantsev, J.L. Marsh, and L.M. Thompson Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity Hum. Mol. Genet 15 2006 273 285 (Pubitemid 43125981)
86. M.R. Sarantos, T. Papanikolaou, L.M. Ellerby, and R.E. Hughes Pizotifen Activates ERK and provides neuroprotection in vitro and in vivo in models of Huntingtons disease J. Huntingtons Dis 1 2012 195 210
87. S. Subramaniam, N. Shahani, J. Strelau, C. Laliberte, R. Brandt, D. Kaplan, and K. Unsicker Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway J. Neurosci. 25 2005 2838 2852 (Pubitemid 40389242)
88. L.P. van der Heide, M.F. Hoekman, G.J. Biessels, and W.H. Gispen Insulin inhibits extracellular regulated kinase 1/2 phosphorylation in a phosphatidylinositol 3-kinase (PI3) kinase-dependent manner in Neuro2a cells J. Neurochem. 86 2003 86 91 (Pubitemid 36753849)
89. F.R. Fusco, S. Anzilotti, C. Giampa, C. Dato, D. Laurenti, A. Leuti, L. Colucci DAmato, L. Perrone, G. Bernardi, and M.A. Melone Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntingtons disease after phosphodiesterase IV inhibition Neurobiol. Dis. 46 2012 225 233
90. T. Milakovic, and G.V. Johnson Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin J. Biol. Chem. 280 2005 30773 30782 (Pubitemid 41291807)
91. R.A. Quintanilla, Y.N. Jin, K. Fuenzalida, M. Bronfman, and G.V. Johnson Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease J. Biol. Chem. 283 2008 25628 25637
92. A.M. Pickrell, H. Fukui, X. Wang, M. Pinto, and C.T. Moraes The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions J. Neurosci. 31 2011 9895 9904
93. K. Acevedo-Torres, L. Berrios, N. Rosario, V. Dufault, S. Skatchkov, M.J. Eaton, and C.A. Torres-Ramos Ayala-Torres, S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntingtons disease DNA Repair (Amst.) 8 2009 126 136
94. C. Richter, J.W. Park, and B.N. Ames Normal oxidative damage to mitochondrial and nuclear DNA is extensive Proc. Natl. Acad. Sci. USA 85 1988 6465 6467
95. J. Kim, J.P. Moody, C.K. Edgerly, O.L. Bordiuk, K. Cormier, K. Smith, M.F. Beal, and R.J. Ferrante Mitochondrial loss, dysfunction and altered dynamics in Huntingtons disease Hum. Mol. Genet 19 2010 3919 3935
96. G.N. Bijur, and R.S. Jope Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation J. Neurochem. 87 2003 1427 1435 (Pubitemid 38020576)
97. H. Yano, S.V. Baranov, O.V. Baranova, J. Kim, Y. Pan, S. Yablonska, D.L. Carlisle, R.J. Ferrante, A.H. Kim, and R.M. Friedlander Inhibition of mitochondrial protein import by mutant huntingtin Nat. Neurosci. 17 2014 822 831
98. E. Taherzadeh-Fard, C. Saft, D.A. Akkad, S. Wieczorek, A. Haghikia, A. Chan, J.T. Epplen, and L. Arning PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease Mol. Neurodegener 6 2011 32